CY1105333T1 - Τροποποιημενα αντισωματα και θραυσματα αντισωματων με αυξημενη διαρκεια δρασης - Google Patents

Τροποποιημενα αντισωματα και θραυσματα αντισωματων με αυξημενη διαρκεια δρασης

Info

Publication number
CY1105333T1
CY1105333T1 CY20061100478T CY061100478T CY1105333T1 CY 1105333 T1 CY1105333 T1 CY 1105333T1 CY 20061100478 T CY20061100478 T CY 20061100478T CY 061100478 T CY061100478 T CY 061100478T CY 1105333 T1 CY1105333 T1 CY 1105333T1
Authority
CY
Cyprus
Prior art keywords
group
antibodies
human
modified antibodies
action
Prior art date
Application number
CY20061100478T
Other languages
English (en)
Inventor
George A. Heavner
Robert W. Weber
Original Assignee
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc. filed Critical Centocor, Inc.
Publication of CY1105333T1 publication Critical patent/CY1105333T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Αποκαλύπτονται τροποποιημένα αντισώματα με βελτιωμένες φαρμακοκινητικές ιδιότητες. Τα αντισώματα προσδένονται σε ένα ή περισσότερους υποδοχείς της ανθρώπινης ενσωματίνης (ιντεγγρίνης) που επιλέγονται από την ομάδα που αποτελείται από GPIIb/IIIa, αvβ3 και Mac-1, και περιλαμβάνουν ένα έως περίπου έξι οργανικά τμήματα τα οποία είναι ομοιοπολικά δεσμευμένα σε συγκεκριμένες τοποθεσίες επί των αντισωμάτων. Τα οργανικά τμήματα μπορούν το καθένα, ανεξάρτητα, να είναι μια υδρόφιλος πολυμερής ομάδα, μια ομάδα λιπαρού οξέος, μια ομάδα εστέρα λιπαρού οξέος, μια ομάδα λιπιδίου ή μια ομάδα φωσφολιπιδίου. Αποκαλύπτεται επίσης μια μέθοδος θεραπείας ενός ανθρώπου με μια ασθένεια ή διαταραχή στην οποία τα κύτταρα που εκφράζουν GPIIb/IIIa, αvβ3 και/ή Mac-1 παίζουν ένα παθοφυσιολογικό ρόλο. Η μέθοδος περιλαμβάνει τη χορήγηση μιας αποτελεσματικής ποσότητας ενός ή περισσοτέρων αντισωμάτων της εφεύρεσης σε ένα άνθρωπο που έχει την ανάγκη τους.
CY20061100478T 1998-11-03 2006-04-03 Τροποποιημενα αντισωματα και θραυσματα αντισωματων με αυξημενη διαρκεια δρασης CY1105333T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18515198A 1998-11-03 1998-11-03
PCT/US1999/025790 WO2000026256A2 (en) 1998-11-03 1999-11-02 Modified antibodies and antibody fragments with increased duration of activity

Publications (1)

Publication Number Publication Date
CY1105333T1 true CY1105333T1 (el) 2010-03-03

Family

ID=22679823

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100478T CY1105333T1 (el) 1998-11-03 2006-04-03 Τροποποιημενα αντισωματα και θραυσματα αντισωματων με αυξημενη διαρκεια δρασης

Country Status (13)

Country Link
EP (1) EP1144452B1 (el)
CN (1) CN1406138A (el)
AT (1) ATE315410T1 (el)
AU (1) AU768295B2 (el)
CA (1) CA2353082A1 (el)
CY (1) CY1105333T1 (el)
DE (1) DE69929467T2 (el)
DK (1) DK1144452T3 (el)
ES (1) ES2257094T3 (el)
MX (1) MXPA01005562A (el)
NZ (1) NZ512055A (el)
PT (1) PT1144452E (el)
WO (1) WO2000026256A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP2184606B1 (en) 2008-11-03 2015-06-24 Helena Laboratories (UK) Ltd. Immunodisplacement Electrophoresis
KR101834890B1 (ko) 2009-10-23 2018-04-20 밀레니엄 파머슈티컬스 인코퍼레이티드 항­ｇｃｃ 항체 분자와 관련 조성물 및 방법
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9073996B2 (en) * 2012-08-31 2015-07-07 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
TWI688406B (zh) * 2017-09-19 2020-03-21 免疫功坊股份有限公司 與白蛋白具有較佳結合親和力之藥物分子
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
ATE124267T1 (de) * 1989-04-03 1995-07-15 Centocor Inc Blutplättchenspezifische immunokonjugate.
JPH11511120A (ja) * 1995-06-07 1999-09-28 セントコー，インコーポレイテッド 血小板特異的キメラ免疫グロブリン及びその使用方法
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
JP2001512480A (ja) * 1997-02-19 2001-08-21 セントコア，インコーポレイテッド 持続的薬物送達およびそれに有用な組成物
CA2288992C (en) * 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof

Also Published As

Publication number Publication date
DE69929467D1 (de) 2006-04-06
AU1907800A (en) 2000-05-22
EP1144452B1 (en) 2006-01-11
PT1144452E (pt) 2006-05-31
WO2000026256A3 (en) 2001-11-08
EP1144452A3 (en) 2002-03-13
CN1406138A (zh) 2003-03-26
AU768295B2 (en) 2003-12-04
DK1144452T3 (da) 2006-05-29
MXPA01005562A (es) 2003-08-01
CA2353082A1 (en) 2000-05-11
EP1144452A2 (en) 2001-10-17
ES2257094T3 (es) 2006-07-16
ATE315410T1 (de) 2006-02-15
WO2000026256A2 (en) 2000-05-11
WO2000026256A9 (en) 2002-08-22
DE69929467T2 (de) 2006-09-28
NZ512055A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
CY1105333T1 (el) Τροποποιημενα αντισωματα και θραυσματα αντισωματων με αυξημενη διαρκεια δρασης
Holley et al. Spectrin, actin and the structure of the cortical lattice in mammalian cochlear outer hair cells
Stowers et al. Dynamic phototuning of 3D hydrogel stiffness
Zhu et al. Potent laminin-inspired antioxidant regenerative dressing accelerates wound healing in diabetes
Mehta et al. Recent advances in targeted drug delivery for treatment of osteoarthritis
Gillies et al. High resolution three‐dimensional reconstruction of fibrotic skeletal muscle extracellular matrix
Brero et al. Methyl CpG–binding proteins induce large-scale chromatin reorganization during terminal differentiation
DE69831402D1 (de) Nicht antigen wirkende verzweigte polymerkonjugate
US8338570B2 (en) Collagen fibrillar construction
BRPI0412637A (pt) anticorpos, método de seleção de um anticorpo de hvegf, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, método de uso do anticorpo e método de tratamento de um mamìfero
FI973048A0 (fi) Menetelmät ja koostumukset hydrofiilisten molekyylien lipidisoimiseksi
Levenson et al. Molecular mechanism of reflectin’s tunable biophotonic control: Opportunities and limitations for new optoelectronics
McClurg et al. Targeting cartilage degradation in osteoarthritis
KR900701302A (ko) 암치료를 위한 신규의 고친화성 변형된 항체군
Phillips et al. Biomimetic proteoglycans diffuse throughout articular cartilage and localize within the pericellular matrix
Thompson et al. Self‐Assembling Hydrogels Crosslinked Solely by Receptor–Ligand Interactions: Tunability, Rationalization of Physical Properties, and 3D Cell Culture
Yoshimura et al. A novel hybrid drug delivery system for treatment of aortic aneurysms
Mukheja et al. Recent advances in pharmaceutical and biotechnological applications of lignin-based materials
Inoue et al. Aggregation-mediated macromolecular uptake by a molecular transporter
Theodorou et al. Rapid Oxygen-Tolerant Synthesis of Protein-Polymer Bioconjugates via Aqueous Copper-Mediated Polymerization
Diao et al. C2AB: a molecular glue for lipid vesicles with a negatively charged surface
Kaji et al. Single‐molecule measurements with a single quantum dot
Sato et al. Induction of spontaneous liposome adsorption by exogenous surface modification with cell-penetrating peptide-conjugated lipids
CN102159256B (zh) 一种用于细胞生长的胶原支架及其制备方法
Magenau et al. Genetically targeted fluorogenic macromolecules for subcellular imaging and cellular perturbation